Literature DB >> 29979995

Elevated interleukin-17 and reduced testosterone in bipolar disorder. Relation with suicidal behaviour.

Neha Keshri1, H Nandeesha2, Shivanand Kattimani1.   

Abstract

Hormonal imbalance and inflammation are associated with bipolar disorder and suicidal behavior. The present study was designed to assess the levels of testosterone and interleukin-17 and their association with suicidal behavior in patients with bipolar disorder in remission. 41 bipolar disorder cases in remission and 41 age matched controls were enrolled in the study. Testosterone and interleukin-17 levels were assessed in both the groups. Interleukin-17 was significantly increased and testosterone was significantly reduced in bipolar disorder when compared with controls. IL-17 was negatively correlated with testosterone (r = -0.368, p = 0.018) and positively correlated with duration of disease (r = 0.382, p = 0.014) in bipolar disorder patients. Both didn't show any association with suicidal behavior. We conclude that testosterone is increased and interleukin-17 is reduced in bipolar disorder in remission and these were not associated with suicidal behavior in these patients.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Disease severity; Inflammation; Interleukin; Suicidal behaviour; Testosterone

Mesh:

Substances:

Year:  2018        PMID: 29979995     DOI: 10.1016/j.ajp.2018.06.011

Source DB:  PubMed          Journal:  Asian J Psychiatr        ISSN: 1876-2018


  2 in total

1.  Study on the relationship between hormone and Lp(a) in Chinese overweight/obese patients.

Authors:  Xiaona Chang; Nannan Bian; Xiaoyu Ding; Jinman Li; Yu An; Jiaxuan Wang; Jia Liu; Guang Wang
Journal:  BMC Endocr Disord       Date:  2022-05-16       Impact factor: 3.263

2.  An Exploratory Cohort Study of the Association between the Level of Testosterone and Suicidal Ideation in Hospitalized Adolescent Females with Depression in China.

Authors:  Yan Liu; Shaohua Wang; Chuang Xue; Xiwen Hu; Guoling Zhou; Yuanyue Zhou; Dan Fang; Kaijing Ding
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-27       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.